(Q43047387)

English

Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy

scientific article published in August 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

author name string

Petra Steindl-Munda

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Peter Ferenci

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Harald Brunner

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Karin Nachbaur

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Christian Datz

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Michael Gschwantler

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Harald Hofer

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Rudolf Stauber

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Franz Hackl

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Wolfgang Jessner

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Martha Rosenbeiger

11

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Alfred Gangl

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Wolfgang Vogel

13

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Austrian Hepatitis Study Group

14

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 August 2003

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Liver International

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

269-275

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

Combination of interferon induction therapy and ribavirin in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

Combination therapy with interferon-alpha 2b and ribavirin for the treatment of relapse patients and non-responders with chronic HCV infection.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, Franc

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

Bile reflux and oesophagitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

21 January 2018

Therapy of hepatitis C: re-treatment with alpha interferon

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

7 January 2021

based on heuristic

inferred from DOI database lookup

National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

7 January 2021

based on heuristic

inferred from DOI database lookup

The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00838.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1034/J.1600-0676.2003.00838.X

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43047387&oldid=1978752433"